Advertisement

Sunscreens and Sun Protection

  • Jason Fallon
  • Gillian M. Murphy
Part of the Cancer Treatment and Research book series (CTAR, volume 146)

Some sun exposure is the norm for human beings. Exposure to ultraviolet radiation (UVR) varies widely depending on behaviour, culture, occupation, and geographic location, particularly latitude and altitude. UV exposure increases by 8% for every 1,000 m in altitude. Ozone depletion of 10% has occurred, mainly affecting sun exposure in countries in the Southern Hemisphere and leading to measurable increase in UVC at the Earth’s surface [1]. One in two Australians, and one in five Americans in the United States, may now expect to develop skin cancer in their lifetime [2]. Skin cancer is the commonest malignancy in the Western world, even in northern latitudes, because such countries are inhabited by people with light-coloured skin.

Keywords

Skin Cancer Basal Cell Carcinoma Renal Transplant Recipient Skin Type Skin Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
  2. 2.
  3. 3.
    Diamond J. Evolutionary biology: geography and skin colour. Nature 2005; 435(7040):283–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Neer RM. The evolutionary significance of vitamin D, skin pigment, and ultraviolet light. Am J Phys Anthropol 1975; 43(3):409–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Branda RF, Eaton JW. Skin color and nutrient photolysis: an evolutionary hypothesis. Science 1978; 201(4356):625–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124(6):869–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Rees JL. The genetics of sun sensitivity in humans. Am J Hum Genet 2004; 75(5):739–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Han J, Kraft P, Colditz GA, et al. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006; 119(8):1976–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Moloney FJ, Comber H, O’Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154(3):498–504.PubMedCrossRefGoogle Scholar
  10. 10.
    Moloney FJ, de Freitas D, Conlon PJ, et al. Renal transplantation, immunosuppression and the skin: an update. Photodermatol Photoimmunol Photomed 2005; 21(1):1–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98(6):389–95.PubMedGoogle Scholar
  12. 12.
    Struijk L, Hall L, van der Meijden E, et al. Markers of cutaneous human papillomavirus infection in individuals with tumor-free skin, actinic keratoses, and squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15(3):529–35.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Connor DP, Kay EW, Leader M, et al. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses? Diagn Mol Pathol 2001; 10(3):190–9.PubMedCrossRefGoogle Scholar
  14. 14.
    O’Connor DP, Kay EW, Leader M, et al. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 2001; 54(7):539–42.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Connor DP, Kay EW, Leader M, et al. A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than Rb. Mol Pathol 2001; 54(3):165–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Giampieri S, Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004; 90(11):2203–9.PubMedGoogle Scholar
  17. 17.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348(17):1681–91.PubMedCrossRefGoogle Scholar
  18. 18.
    185–91. Review. Photochem Photobiol 1995; 61(6):615–8.Google Scholar
  19. 19.
    Diffey BL, Saunders PJ. Behaviour outdoors and its effects on personal ultraviolet exposure rate measured using an ambulatory datalogging dosimeter. Photochem Photobiol 1995; 61(6):615–8.PubMedGoogle Scholar
  20. 20.
    Gies HP, Roy CR, McLennan A, et al. UV protection by clothing: an intercomparison of measurements and methods. Health Phys 1997; 73(3):456–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Thieden E, Collins SM, Philipsen PA, et al. Ultraviolet exposure patterns of Irish and Danish gardeners during work and leisure. Br J Dermatol 2005; 153(4):795–801.PubMedCrossRefGoogle Scholar
  22. 22.
    Diffey BL, Diffey JL. Sun protection with trees. Br J Dermatol 2002; 147(2):397–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Urbach F. The historical aspects of sunscreens. J Photochem Photobiol B 2001; 64:99–104.PubMedCrossRefGoogle Scholar
  24. 24.
    Nash JF. Human safety and efficacy of ultraviolet filters and sunscreen products. Dermatol Clin 2006; 24(1):35–51.PubMedCrossRefGoogle Scholar
  25. 25.
    The European Cosmetic, Toiletry and Perfumery Association (COLIPA) International Sun Protection Factor (SPF) Test Method. Brussels: The European Cosmetic, Toiletry, and Perfumery Association, 2003.Google Scholar
  26. 26.
    Diffey BL, Tanner PR, Matts PJ, et al. In vitro assessment of the broad-spectrum ultraviolet protection of sunscreen products. J Am Acad Dermatol 2000; 43(6):1024–35.PubMedCrossRefGoogle Scholar
  27. 27.
    Cole C. Sunscreen protection in the ultraviolet A region: how to measure the effectiveness. Photodermatol Photoimmunol Photomed 2001; 17(1):2–10.PubMedCrossRefGoogle Scholar
  28. 28.
    U.S. Food and Drugs Administration. The Final Over-the-Counter Drug Monograph on Sunscreens (Federal Register 1999; 64:27666–27963). http://www.fda.gov/ohrms/dockets/98fr/052199b.pdf
  29. 29.
    European Commission Cosmetic Directive. Annex VII: List of permitted UV filters which cosmetic products may contain. From: The Council Directive on the approximation of the laws of the Member States relating to cosmetic products 76/768/EEC. Official Jo L 2005 update (pp 102–108). http://europa.eu.int/eurlex/lex/LexUriServ/site/en/ consleg/1976/L/01976L0768-20050913-en.pdf:
  30. 30.
    Nohynek GJ, Schaefer H. Benefit and risk of organic ultraviolet filters. Regul Toxicol Pharmacol 2001; 33(3):285–99.PubMedCrossRefGoogle Scholar
  31. 31.
    European Commission. Commission Decision of 8 May 1996 establishing an inventory and a common nomenclature of ingredients employed in cosmetic products 96/335/EC84. Official Jo L 1996; 132:1–684. http://ec.europa.eu/enterprise/cosmetics/inci/inci_2006.pdf
  32. 32.
    US Food and Drugs Administration. Sunscreen Drug Products for Human Use. Centre for Devices and Radiological Health Part 352. Fed Reg 67(No. 119), 2002. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=352&showFR=1
  33. 33.
    IARC. Handbooks on Cancer Prevention, vol 5. Lyon: IARC Press, 2001.Google Scholar
  34. 34.
    Darlington S, Williams G, Neale R, et al. A randomized controlled trial to assess sunscreen application and betacarotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003; 139(4):451–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354(9180):723–9. Erratum in: Lancet 1999; 354(9183):1038.Google Scholar
  36. 36.
    Moloney FJ, Almarzouqi E, O’Kelly P, et al. Sunscreen use before and after transplantation and assessment of risk factors associated with skin cancer development in renal transplant recipients. Arch Dermatol 2005; 141(8):978–82.PubMedCrossRefGoogle Scholar
  37. 37.
    Moloney FJ, Comber H, Conlon PJ, et al. The role of immunosuppression in the pathogenesis of basal cell carcinoma. Br J Dermatol 2006; 154(4):790–1.PubMedCrossRefGoogle Scholar
  38. 38.
    Laing ME, Moloney FJ, Comber H, et al. Malignant melanoma in renal transplant recipients. Br J Dermatol 2006; 155(4):857.PubMedCrossRefGoogle Scholar
  39. 39.
    Laing ME, Moloney FJ, Kay EW, et al. Malignant melanoma in transplant patients: review of five cases. Clin Exp Dermatol 2006; 31(5):662–4.PubMedCrossRefGoogle Scholar
  40. 40.
    D’Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006; 443(7109):340–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Barnetson RSC, Ooi TKT, Zhuang L, et al. [Nle4-D-Phe7] – Melanocyte-StimulatingHormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers. J Invest Dermat 2006; 126:1869–78.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jason Fallon
    • 1
  • Gillian M. Murphy
    • 2
  1. 1.Department of DermatologyBeaumont Hospital, DublinIreland
  2. 2.Department of DermatologyBeaumont and Mater Misericordiae Hospitals and Royal College of Surgeons in IrelandDublinIreland

Personalised recommendations